We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

126 hedge funds and large institutions have $53.8M invested in Lineage Cell Therapeutics in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 16

115% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 13

11% more funds holding

Funds holding: 114 → 126 (+12)

1.48% less ownership

Funds ownership: 50.08% → 48.6% (-1.5%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

37% less capital invested

Capital invested by funds: $85.6M → $53.8M (-$31.8M)

Holders
126
Holders Change
+12
Holders Change %
+10.53%
% of All Funds
1.66%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
28
Increased
38
Reduced
16
Closed
13
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
-$20K

Top Buyers

1
PA
Perceptive Advisors
New York
+$5.31M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.9M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.53M
4
DCM
DAFNA Capital Management
California
+$852K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$759K

Top Sellers

1
LGM
Logos Global Management
California
-$4.53M
2
Bank of America
Bank of America
North Carolina
-$980K
3
MCM
MAI Capital Management
Ohio
-$747K
4
BCM
Bridgeway Capital Management
Texas
-$249K
5
LFCM
Long Focus Capital Management
Puerto Rico
-$195K
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
126
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$52.5K -57,953 Closed
D.E. Shaw & Co
127
D.E. Shaw & Co
New York
– -$23.2K -25,584 Closed
PVI
128
Pine Valley Investments
New Jersey
– -$16.3K -18,000 Closed
SPWM
129
Straight Path Wealth Management
Michigan
– -$14.7K -16,200 Closed
FCMT
130
Founders Capital Management (Texas)
Texas
– -$13.6K -15,000 Closed
MFS
131
Madrona Financial Services
Washington
– -$13.6K -15,000 Closed
TSS
132
Two Sigma Securities
New York
– -$12.6K -13,941 Closed
EGM
133
Engineers Gate Manager
New York
– -$10.4K -11,458 Closed
Simplex Trading
134
Simplex Trading
Illinois
– -$807 -1,099 -76%
Group One Trading
135
Group One Trading
Illinois
– -$547 -745 Closed
CPA
136
Capital Performance Advisors
California
– -$148 -163 Closed
NFSG
137
Newbridge Financial Services Group
Florida
– -$5 -5 Closed
2 3 4 5
6

LCTX Hedge Fund Activity: Q4 2024 in Review

126 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2024, worth a combined $53.8M — down 37% from $85.6M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new LCTX positions and 13 closed out — a net gain of 15 holders — while 38 added to existing stakes and 16 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.31M. The largest seller was Logos Global Management, exiting entirely with an estimated $4.53M sold.

  • 126 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2024, up from 114 in Q3 2024.
  • Funds reported $53.8M of Lineage Cell Therapeutics stock for Q4 2024, down 37% quarter-over-quarter.
  • 28 funds opened new Lineage Cell Therapeutics positions in Q4 2024 and 13 closed out, a net change of +15 holders.
  • The largest Lineage Cell Therapeutics buyer in Q4 2024 was Perceptive Advisors, an estimated $5.31M added.
  • The largest Lineage Cell Therapeutics seller in Q4 2024 was Logos Global Management, an estimated $4.53M sold.

Based on aggregated 13F filings for Q4 2024.